The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.

Published on May 7, 2021in Molecular Medicine4.096
· DOI :10.1186/S10020-021-00306-2
Marta Poźniak (UWr: University of Wrocław), Natalia Porębska3
Estimated H-index: 3
(UWr: University of Wrocław)
+ 7 AuthorsŁukasz Opaliński7
Estimated H-index: 7
(UWr: University of Wrocław)
BACKGROUND Antibody drug conjugates (ADCs) represent one of the most promising approaches in the current immuno-oncology research. The precise delivery of cytotoxic drugs to the cancer cells using ADCs specific for tumor-associated antigens enables sparing the healthy cells and thereby reduces unwanted side effects. Overexpression of fibroblast growth factor receptor 1 (FGFR1) has been demonstrated in numerous tumors and thereby constitutes a convenient molecular target for selective cancer treatment. We have recently engineered tetravalent anti-FGFR1 antibody, T-Fc, and have demonstrated that it displays extremely efficient internalization into FGFR1 producing cells, a feature highly desirable in the ADC approach. We have revealed that T-Fc mediates clustering of FGFR1, largely enhancing the uptake of FGFR1-T-Fc complexes by induction of clathrin-independent endocytic routes. The aim of this study was to obtain highly internalizing cytotoxic conjugate of the T-Fc for specific delivery of drugs into FGFR1-positive cancer cells. METHODS Conjugation of the T-Fc to a cytotoxic payload, vcMMAE, was carried out via maleimide chemistry, yielding the T-Fc-vcMMAE. The specific binding of the T-Fc-vcMMAE conjugate to FGFR1 was confirmed in vitro with BLI technique. Confocal microscopy and flow cytometry were applied to determine FGFR1-dependence of the T-Fc-vcMMAE internalization. Western blot analyses of FGFR1-dependent signaling were conducted to assess the impact of the T-Fc-vcMMAE on FGFR1 activation and initiation of downstream signaling cascades. Finally, using FGFR1-negative and FGFR1-possitive cell lines, the cytotoxic potential of the T-Fc-vcMMAE was evaluated. RESULTS We have performed the efficient conjugation of the tetravalent engineered antibody with a cytotoxic drug and generated FGFR1-specific ADC molecule, T-Fc-vcMMAE. We have demonstrated that T-Fc-vcMMAE conjugate exhibits high selectivity and affinity for FGFR1, similarly to T-Fc. Furthermore, we have shown that T-Fc constitutes an effective drug delivery vehicle as T-Fc-vcMMAE was efficiently and selectively internalized by FGFR1-producing cells leading to their death. Interestingly, we show that the efficiency of the uptake of T-Fc-vcMMAE corresponds well with the cytotoxicity of the conjugate, but doesn't correlate with the FGFR1expression level. CONCLUSION Our results show that T-Fc-vcMMAE fulfills the key criteria for the successful cytotoxic drug carrier in a targeted approach against FGFR1-positive cancer cells. Furthermore, our data implicate that not solely expression level of the receptor, but rather its cellular trafficking should be taken into account for selection of suitable molecular targets and cancer models for successful ADC approach.
#1Elaine Chang (CDER: Center for Drug Evaluation and Research)H-Index: 6
#2Chana Weinstock (CDER: Center for Drug Evaluation and Research)H-Index: 6
Last. Julia A. Beaver (FDA: Food and Drug Administration)H-Index: 25
view all 19 authors...
On December 18, 2019, the Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (PADCEV; Astellas and Seattle Genetics) for treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Substantial evidence of effectiveness for this application is obtained from Cohort 1 of the single ...
12 CitationsSource
#1Anthony Markham (Springer Science+Business Media)H-Index: 20
Belantamab mafodotin (BLENREP™; belantamab mafodotin-blmf) is a first-in-class monoclonal antibody-drug conjugate (ADC) that has been developed for the treatment of multiple myeloma by GlaxoSmithKline. The ADC comprises an antibody targeting B-cell maturation antigen (BCMA) conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF). The antibody moiety binds to BCMA on the tumour cell surface, delivering the cytotoxic microtubule inhibitor MMAF to the therapeutic target. Based on pre...
20 CitationsSource
#1Zu-Chian Chiang (AS: Academia Sinica)H-Index: 1
#2Chiu Yi-Kai (AS: Academia Sinica)H-Index: 3
Last. Andrew H.-J. Wang (AS: Academia Sinica)H-Index: 93
view all 10 authors...
Two systems of antibody-drug conjugates (ADCs), noncleavable H32-DM1 and cleavable H32-VCMMAE, were developed by using different linkers and drugs attached to the anti-HER2 antibody H32, which is capable of cell internalization. Activated functional groups, including an N-hydroxysuccinimidyl (NHS) ester and a maleimide, were utilized to make the ADCs. Mass spectrometry, hydrophobic interaction chromatography, polyacrylamide gel electrophoresis, and in vitro cell assays were performed to analyze ...
1 CitationsSource
#1Marta Pozniak (UWr: University of Wrocław)H-Index: 1
#2Aleksandra Sokolowska-Wedzina (UWr: University of Wrocław)H-Index: 7
Last. Lukasz Opalinski (UWr: University of Wrocław)H-Index: 3
view all 10 authors...
Fibroblast growth factor receptor 1 (FGFR1) transmits signals through the plasma membrane regulating essential cellular processes like division, motility, metabolism and death. Overexpression of FGFR1 is observed in numerous tumors and thus constitutes an attractive molecular target for selective cancer treatment. Targeted anti-cancer therapies aim for the precise delivery of drugs into cancer cells, sparing the healthy ones and thus limiting unwanted side effects. One of the key steps in target...
3 CitationsSource
#1Pengxuan Zhao (HUST: Huazhong University of Science and Technology)H-Index: 2
#2Yuebao Zhang (OSU: Ohio State University)H-Index: 1
Last. Yizhou DongH-Index: 28
view all 6 authors...
Abstract Antibody drug conjugates (ADCs) normally compose of a humanized antibody and small molecular drug via a chemical linker. After decades of preclinical and clinical studies, a series of ADCs have been widely used for treating specific tumor types in the clinic such as brentuximab vedotin (Adcetris®) for relapsed Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma, gemtuzumab ozogamicin (Mylotarg®) for acute myeloid leukemia, ado-trastuzumab emtansine (Kadcyla®) for HER2-positiv...
20 CitationsSource
In spite of significant progress in the field of targeted anticancer therapy, the FDA has approved only five ADC-based drugs. Hence the search for new targeted anticancer agents is an unfulfilled n...
3 CitationsSource
#1Yahiya Y. Syed (Springer Science+Business Media)H-Index: 17
Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the USA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Sacituzumab govite...
30 CitationsSource
#1Susan J. Keam (Springer Science+Business Media)H-Index: 16
Trastuzumab deruxtecan (ENHERTU®), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumours, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca. Based primarily on the results of the phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan was recently approved in the USA under accelerated approval for the treatmen...
35 CitationsSource
#1Sharad Sharma (UB: University at Buffalo)H-Index: 7
#2Zhe Li (UB: University at Buffalo)H-Index: 5
Last. Dhaval K. Shah (UB: University at Buffalo)H-Index: 18
view all 4 authors...
Antibody-drug conjugates (ADCs) employ overexpressed cell surface antigens to deliver cytotoxic payloads inside cancer cells. However, the relationship between target expression and ADC efficacy remains ambiguous. In this manuscript we have addressed a part of this ambiguity by quantitatively investigating the effect of antigen expression levels on ADC exposure within cancer cells. Trastuzumab-vc-MMAE was used as a model ADC, and four different cell lines with diverse levels of human epidermal g...
5 CitationsSource
#1Puregmaa Khongorzul (CPU: China Pharmaceutical University)H-Index: 3
#2Cai Jia Ling (CPU: China Pharmaceutical University)H-Index: 1
Last. Juan Zhang (CPU: China Pharmaceutical University)H-Index: 1
view all 5 authors...
Antibody-drug conjugates (ADCs) are one of the fastest-growing anti-cancer drugs. This approach comprises a monoclonal antibody conjugated to the cytotoxic payload via a chemical linker that directed towards a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. ADCs are complex molecules that require careful attention to various components. Selection of an appropriate target, a monoclonal antibody, cytotoxic payload, and the manner in which the...
101 CitationsSource
Cited By1
#1Marta Poźniak (UWr: University of Wrocław)
#2Weronika Zarzycka (UWr: University of Wrocław)
Last. Łukasz Opaliński (UWr: University of Wrocław)H-Index: 7
view all 8 authors...
FGFRs are cell surface receptors that, when activated by specific FGFs ligands, transmit signals through the plasma membrane, regulating key cellular processes such as differentiation, division, motility, metabolism and death. We have recently shown that the modulation of the spatial distribution of FGFR1 at the cell surface constitutes an additional mechanism for fine-tuning cellular signaling. Depending on the multivalent, engineered ligand used, the clustering of FGFR1 into diverse supramolec...